Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Prurisedán** is an Argentine topical antipruritic pharmaceutical brand family marketed by Andrómaco, rather than one chemically uniform drug. The currently identified presentations include an over-the-counter cream containing diphenhydramine hydrochloride plus calamine, an over-the-counter clear lotion containing diphenhydramine hydrochloride plus zinc oxide, and a prescription powder containing boric acid plus zinc oxide. The diphenhydramine-containing products provide local antihistaminic relief of itch, while calamine or zinc oxide provide protective, soothing, and drying effects; the powder formulation is described as antipruritic, antiseptic, and astringent, with boric acid contributing local bacteriostatic activity. The product line is used for symptomatic relief of pruritus and selected superficial inflammatory or irritant skin conditions, including insect bites, contact dermatitis, sunburn, urticaria, miliaria, and moist or blistering pruritic lesions. ([prurisedan.com.ar](https://www.prurisedan.com.ar/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Prurisedán.